MT2018-18: Sleeping Beauty Transposon-Engineered Plasmablasts for Hurler Syndrome Post Allo HSCT

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study went on hold because more pre-clinical work needs to be done per FDA feedback. However, the study never went off hold and the study team has decided to close this study without opening to enrollment.

Conditions

Mucopolysaccharidosis Type IH (MPS IH, Hurler Syndrome)
Mucopolysaccharidosis Type IH
MPS IH, Hurler Syndrome

Interventions

DRUG: Autologous Plasmablasts

Sponsor

Masonic Cancer Center, University of Minnesota